Adult T-cell leukemia/lymphoma (ATL) is caused by Human T-cell lymphotropic/leukemia virus type 1 (HTLV-1), and a higher HTLV-1 provirus load in PBMC is a risk factor for ATL development. Here, we document a significant inverse correlation between the function of HTLV-1 Tax-specific CTL (Tax-CTL), as assessed by ex vivo cytokine production in response to cognate peptide, and the HTLV-1 provirus load in PBMC in both HTLV-1 asymptomatic carriers (AC) (Spearman rank correlation coefficient [Rs] = À0.494, P = .037, n = 18) and ATL patients (Rs = À0.774, P = .001, n = 15). There was also a significant correlation between the HTLV-1 provirus load and the percentage of PD-1-positive Tax-CTL in both HTLV-1 AC (Rs = 0.574, P = .013) and ATL patients (Rs = 0.676, P = .006). Furthermore, the percentage of PD-1-positive Tax-CTL was inversely correlated with their function in HTLV-1 AC (Rs = À0.542, P = .020), and ATL patients (Rs = À0.639, P = .010).
response for many years, and that eventually a small number escape immunosurveillance and develop into overt ATL. In this scenario, it is important to understand which antigens on the HTLV-1-infected cells are or could be targeted by the host immune response. HTLV-1-associated antigens such as Tax or HBZ, [5] [6] [7] cancer testis antigens, 8 or neoantigens arising as a consequence of 
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tumor-specific mutations 9, 10 are all candidates. Of these candidates, immunogenicity of HBZ is not strong. 2, 3 We previously reported that HTLV-1 transmission from mothers to infants through breast milk in early life might induce tolerance to HBZ and result in insufficient HBZ-specific T-cell responses in HTLV-1 asymptomatic carriers or ATL patients. 7 Cancer testis antigen expression profiles in ATL are variable, thus reducing their utility as therapeutic targets as well. 8 Neoantigens are, by definition, most likely limited to individual cases. 9, 10 Therefore, here we focused on Tax, which is obligatory for transformation of infected cells by HTLV-1, 11 and which is relatively strongly immunogenic. 2, 3, 5, 6 We explored the relationship between the function of HTLV-1 Tax-specific CTL (Tax-CTL) and the HTLV-1 provirus load in PBMC.
| PATIENTS AND METHODS

| Primary cells from HTLV-1 AC or ATL patients
PBMC were isolated from 18 HTLV-1 AC and 15 ATL patients using
Ficoll-Paque centrifugation (Pharmacia, Uppsala, Sweden). Of the 15 ATL patients, 1 with a chronic and 1 with a smoldering subtype were carefully observed using a watch-and-wait approach. Among the remaining 13 patients, 9 had been in remission for aggressive ATL after systemic chemotherapy and/or treatment with mogamulizumab 12-14 for more than 6 months before blood draw for the present study. The remaining 4 were in remission after allogeneic hematopoietic stem cell transplantation (HSCT) from an unrelated HTLV-1-negative donor more than 2 years earlier. The transplanted patients had been free of any immunosuppressive treatment for more than 6 months prior to the study. All donors provided written informed consent before sampling, according to the Declaration of Helsinki, and the present study was approved by the institutional ethics committee of Nagoya City University Graduate School of Medical Sciences. 
| Human leukocyte antigen typing
| Absolute number of Tax-CTL
Absolute numbers of PD-1-positive and -negative Tax-CTL were calculated from the total lymphocyte count (/lL) and the percentages of PD-1-positive and -negative Tax-CTL in this population.
| Statistical analysis
Correlations between 2 variables were assessed using the Spearman rank correlation coefficient (Rs). The analyses were carried out with SPSS Statistics 17.0 (IBM Corporation, Armonk, NY, USA). In this study, P < .05 (two-sided) was considered significant.
| RESULTS
There expression on Tax-CTL, and cytokine production in response to cognate peptide, is shown in Figure 1D (for HTLV-1 AC numbers 1-4).
Next, we undertook the same analysis with ATL patients. As Figure 3A) or PD-1-positive Tax-CTL (Rs = 0.126, P = .618) ( Figure 3B ). In contrast, in ATL patients, there was a significant inverse correlation between the HTLV-1 provirus load in PBMC and the absolute number of PD-1-negative Tax-CTL (Rs = À0.561, P = .029) ( Figure 1C ). However, no such correlation was seen for the absolute number of PD-1-positive Tax-CTL (Rs = À0.061, P = .830) ( Figure 1D ).
| DISCUSSION
The findings from the present study are consistent with the phenomenon of "T-cell exhaustion" in both HTLV-1 AC and ATL patients, 15, 16 similar to what has been reported in other chronic viral infections such as hepatitis B virus, 17 hepatitis C virus, 18 human immunodeficiency virus (HIV) infections, 19 and also in cancer. 20 The present study indicates that persistent continuous exposure of Tax targeting PD-1 should also be effective for ATL patients. Accordingly, we are now conducting an investigator-initiated phase II study of nivolumab for relapsed/refractory ATL (UMIN000020601). However, in this respect, it must be noted that rapid progression of ATL after nivolumab treatment has been reported by other investigators. 22 The mechanisms responsible for ATL progression on nivolumab have not yet been determined, but, clearly, great caution is required in our own phase II study of nivolumab for ATL. Although TIM-3, LAG-3 and CTLA-4 have also been reported to be markers of exhausted T-cells, 15, 16 the present study showed that these were not reliable markers of Tax-CTL exhaustion. The reason for this is not clear, but it is conceivable that appropriate markers of exhaustion might vary according to the type of CTL.
Allogeneic HSCT is considered to be the only curative treatment for aggressive ATL. 23, 24 In this context, it is notable that the functions of the Tax-CTL originating from HTLV-1-negative donors in the present transplanted patients were generally well retained, and the fraction of PD-1-positive cells was low. This is likely to be related to the control of HTLV-1-infected cells in these patients after allogeneic HSCT. Although an earlier study analyzed PD-1 expression in general on lymphocytes in HTLV-1 AC or in ATL patients comprehensively, 25 the present study quantified PD-1 expression levels on Tax-CTL. Relating these to the HTLV-1 provirus load in PBMC and to the functional integrity of Tax-CTL has not been previously reported. Herein lies the novelty and significance of this work.
In conclusion, the functional integrity of Tax-CTL is crucial for determining HTLV-1 provirus load in PBMC not only in HTLV-1 AC, but also in ATL patients. Exploiting the immunological equilibrium between Tax-CTL vs HTLV-1-infected cells to achieve long-term dominance of functional Tax-CTL would represent an ideal strategy for controlling HTLV-1-associated disease.
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